Psoriasis In Patients With Active Lung Cancer: Is Apremilast a Safe Option?

Código QR

Psoriasis In Patients With Active Lung Cancer: Is Apremilast a Safe Option?

Guardado en:

Detalles Bibliográficos
Autores principales:	Zoe Apalla, Eftychios Psarakis, Aimilios Lallas, Alexia Koukouthaki, Athanassios Fassas, Maria Smaragdi
Formato:	article
Lenguaje:	EN
Publicado:	Mattioli1885 2019
Materias:	psoriasis adenocarcinoma apremilast phosphodiesterase inhibitor treatment Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/a5f7175648b64ccf951595665b8ec48b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
por: Rajagopalan M, et al.
Publicado: (2021)

Modification of Apremilast from Pills to Aerosol a Future Concept
por: Paul Zarogoulidis, et al.
Publicado: (2021)

Phosphodiesterase-4 Inhibition in Psoriasis
por: Milakovic M, et al.
Publicado: (2021)

Dermoscopic hemorrhagic dots: an early predictor of response of psoriasis to biologic agents
por: Aimilios Lallas, et al.
Publicado: (2016)

Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
por: Lanna C, et al.
Publicado: (2019)

Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats
por: Anwer MK, et al.
Publicado: (2019)

Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
por: Smirnova LM, et al.
Publicado: (2019)

Atypical case of lichen planus recognized by dermoscopy
por: Chrysoula Papageorgiou, et al.
Publicado: (2016)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Yuliya Lytvyn, PhD, et al.
Publicado: (2022)

Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial
por: Luis Puig, et al.
Publicado: (2021)

Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer S, et al.
Publicado: (2015)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
por: Yang EJ, et al.
Publicado: (2018)

Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy
por: Abhijeet Kumar Jha, et al.
Publicado: (2018)

Pustular psoriasis: pathophysiology and current treatment perspectives
por: Benjegerdes KE, et al.
Publicado: (2016)

Management of scalp psoriasis: current perspectives
por: Blakely K, et al.
Publicado: (2016)

Psoriasis and alcohol
por: Svanström C, et al.
Publicado: (2019)

Updates on the Treatment of Erythrodermic Psoriasis
por: Lo Y, et al.
Publicado: (2021)

Tratamiento crónico combinado con iloprost y sildenafil en un paciente con hipertensión pulmonar primaria
por: Isa P,Rodrigo, et al.
Publicado: (2004)

Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
por: Annunziata Dattola, et al.
Publicado: (2021)

Psoriasis and uveitis: links and risks
por: Fotiadou C, et al.
Publicado: (2019)

Diagnosis and screening of patients with generalized pustular psoriasis
por: Ly K, et al.
Publicado: (2019)

Psoriasis: Targets and Therapy
Publicado: (2012)

An Atypical Case of Pustular Psoriasis Presenting With Severe Subungual Abscesses Involving All Fingers
por: A. Tulin Mansur
Publicado: (2019)

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
por: Chiricozzi A, et al.
Publicado: (2019)

The new external drug for the treatment of psoriasis based on inhibition of serine proteases
por: Alexander S. Zhukov, et al.
Publicado: (2021)

The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice
por: Georgios Kokolakis, et al.
Publicado: (2021)

Current knowledge on psoriasis and autoimmune diseases
por: Ayala-Fontánez N, et al.
Publicado: (2016)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado Á, et al.
Publicado: (2018)

Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health
por: Teklu M, et al.
Publicado: (2021)

Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic
por: Haulrig MB, et al.
Publicado: (2021)

Monitoring treatment response in psoriasis: current perspectives on the clinical utility of reflectance confocal microscopy
por: Agozzino M, et al.
Publicado: (2017)

Psoriasis
por: MOLL LEE,NORMAN
Publicado: (1947)

Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India
por: Budamakuntla L, et al.
Publicado: (2019)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
por: Zoe Apalla, et al.
Publicado: (2021)

Serum TSLP is a potential biomarker of psoriasis vulgaris activity
por: El-Ghareeb MI, et al.
Publicado: (2019)

Assessment and monitoring of biologic drug adverse events in patients with psoriasis
por: Hanley T, et al.
Publicado: (2016)

Erythrodermic psoriasis: pathophysiology and current treatment perspectives
por: Singh RK, et al.
Publicado: (2016)

Impact of Etanercept on Vitamin D Status and Vitamin D-binding Protein in Bio-naïve Patients with Psoriasis
por: Maria Siekkeri Vandikas, et al.
Publicado: (2021)

The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials
por: Mateusz Socha, et al.
Publicado: (2019)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton P, et al.
Publicado: (2021)